{"id":73551,"date":"2026-05-22T11:47:00","date_gmt":"2026-05-22T11:47:00","guid":{"rendered":"https:\/\/flamenet.io\/2026\/05\/22\/in-first-line-metastatic-triple-negative-breast-cancer-for-patients-not-candidates-for-pd-l1-inhibitors-business-wire\/"},"modified":"2026-05-22T11:47:00","modified_gmt":"2026-05-22T11:47:00","slug":"in-first-line-metastatic-triple-negative-breast-cancer-for-patients-not-candidates-for-pd-l1-inhibitors-business-wire","status":"publish","type":"post","link":"https:\/\/flamenet.io\/2026\/05\/22\/in-first-line-metastatic-triple-negative-breast-cancer-for-patients-not-candidates-for-pd-l1-inhibitors-business-wire\/","title":{"rendered":"in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors &#8211; Business Wire"},"content":{"rendered":"<p><a href=\"https:\/\/news.google.com\/rss\/articles\/CBMitgJBVV95cUxOMjZsVVhVcXNIeF9wRTRzNV85M1kzU3k1MnkyX1J3OGlieWJkN21oSXYxZzcteUVqa2ZRS1hsYkMzVTIwSU9DWDRZMUhXVF9xSUtuRmd0a0xYSGpCZ0hNMUtGTzQxOWlLSnhMTXU2anJiLUZJM0p2dGR2V2lwbFp0aUE4NTdFWExyZGduaTNvSlNWdFZwMXVjRlZGZFNUQkxOZjM1Nm1EMi1ISDBBa19zWEhWaGVMSlFHR1hENkV2eUw5bHU3ZERGb2Mxd0VUSGpMMWRkTFZmU2VKMmlkM3B4cVV0SXZ6SVhmNzJVdVRBZzl5UUFpbE5iX1o1cUtBVUNYVVN4RjRUU0h3Ynp0ZUxqRW1WdEZ6UnJlcUxvSkhQdlVvb2o5Um92TEdtQm9qZnNYZFZGX0J3?oc=5\" target=\"_blank\">in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors<\/a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Business Wire<\/font><\/p>\n","protected":false},"excerpt":{"rendered":"<p>in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors&nbsp;&nbsp;Business Wire<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[],"class_list":["post-73551","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/73551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/comments?post=73551"}],"version-history":[{"count":0,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/73551\/revisions"}],"wp:attachment":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/media?parent=73551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/categories?post=73551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/tags?post=73551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}